Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/PLK2_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PLK2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PLK2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PLK2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PLK2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PLK2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PLK2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00321024 | Skin | AK | negative regulation of response to external stimulus | 61/1910 | 420/18723 | 2.96e-03 | 1.87e-02 | 61 |
GO:00109485 | Skin | AK | negative regulation of cell cycle process | 45/1910 | 294/18723 | 3.73e-03 | 2.22e-02 | 45 |
GO:004312319 | Skin | AK | positive regulation of I-kappaB kinase/NF-kappaB signaling | 31/1910 | 186/18723 | 4.21e-03 | 2.46e-02 | 31 |
GO:00315706 | Skin | AK | DNA integrity checkpoint | 22/1910 | 123/18723 | 6.33e-03 | 3.38e-02 | 22 |
GO:00000755 | Skin | AK | cell cycle checkpoint | 28/1910 | 169/18723 | 6.83e-03 | 3.60e-02 | 28 |
GO:0042176112 | Skin | SCCIS | regulation of protein catabolic process | 54/919 | 391/18723 | 5.60e-12 | 7.43e-09 | 54 |
GO:1903362112 | Skin | SCCIS | regulation of cellular protein catabolic process | 38/919 | 255/18723 | 9.24e-10 | 5.45e-07 | 38 |
GO:001635818 | Skin | SCCIS | dendrite development | 36/919 | 243/18723 | 3.00e-09 | 1.45e-06 | 36 |
GO:0045732112 | Skin | SCCIS | positive regulation of protein catabolic process | 34/919 | 231/18723 | 9.75e-09 | 3.45e-06 | 34 |
GO:1903364112 | Skin | SCCIS | positive regulation of cellular protein catabolic process | 26/919 | 155/18723 | 3.64e-08 | 7.72e-06 | 26 |
GO:1903050112 | Skin | SCCIS | regulation of proteolysis involved in cellular protein catabolic process | 32/919 | 221/18723 | 3.93e-08 | 7.72e-06 | 32 |
GO:000268318 | Skin | SCCIS | negative regulation of immune system process | 49/919 | 434/18723 | 4.92e-08 | 8.19e-06 | 49 |
GO:0007568110 | Skin | SCCIS | aging | 41/919 | 339/18723 | 9.54e-08 | 1.29e-05 | 41 |
GO:2000058112 | Skin | SCCIS | regulation of ubiquitin-dependent protein catabolic process | 26/919 | 164/18723 | 1.18e-07 | 1.52e-05 | 26 |
GO:0010631110 | Skin | SCCIS | epithelial cell migration | 42/919 | 357/18723 | 1.45e-07 | 1.74e-05 | 42 |
GO:0045862112 | Skin | SCCIS | positive regulation of proteolysis | 43/919 | 372/18723 | 1.69e-07 | 1.91e-05 | 43 |
GO:0090132110 | Skin | SCCIS | epithelium migration | 42/919 | 360/18723 | 1.82e-07 | 1.97e-05 | 42 |
GO:0090130110 | Skin | SCCIS | tissue migration | 42/919 | 365/18723 | 2.66e-07 | 2.62e-05 | 42 |
GO:0061136112 | Skin | SCCIS | regulation of proteasomal protein catabolic process | 26/919 | 187/18723 | 1.60e-06 | 9.11e-05 | 26 |
GO:0001667111 | Skin | SCCIS | ameboidal-type cell migration | 48/919 | 475/18723 | 1.78e-06 | 9.73e-05 | 48 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PLK2 | SNV | Missense_Mutation | | c.1468N>C | p.Asp490His | p.D490H | Q9NYY3 | protein_coding | deleterious(0.03) | benign(0.438) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PLK2 | SNV | Missense_Mutation | novel | c.1034N>A | p.Ser345Tyr | p.S345Y | Q9NYY3 | protein_coding | deleterious(0.04) | benign(0.212) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLK2 | SNV | Missense_Mutation | novel | c.412N>T | p.His138Tyr | p.H138Y | Q9NYY3 | protein_coding | deleterious(0.02) | possibly_damaging(0.808) | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PLK2 | SNV | Missense_Mutation | novel | c.622C>G | p.Leu208Val | p.L208V | Q9NYY3 | protein_coding | deleterious(0.03) | possibly_damaging(0.879) | TCGA-OL-A5S0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxol | CR |
PLK2 | insertion | Frame_Shift_Ins | novel | c.1417_1418insCAAA | p.Asp473AlafsTer19 | p.D473Afs*19 | Q9NYY3 | protein_coding | | | TCGA-A8-A07G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
PLK2 | insertion | Nonsense_Mutation | novel | c.1416_1417insTAGGCCCCTAAAGATATCAGAAGCATAAAATTATAAA | p.Asp473Ter | p.D473* | Q9NYY3 | protein_coding | | | TCGA-A8-A07G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
PLK2 | insertion | Frame_Shift_Ins | novel | c.409_410insATTTACGACT | p.Leu137HisfsTer7 | p.L137Hfs*7 | Q9NYY3 | protein_coding | | | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PLK2 | deletion | Frame_Shift_Del | novel | c.1327delN | p.Asp443MetfsTer5 | p.D443Mfs*5 | Q9NYY3 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
PLK2 | SNV | Missense_Mutation | novel | c.1961C>A | p.Thr654Asn | p.T654N | Q9NYY3 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-VS-A9UP-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
PLK2 | SNV | Missense_Mutation | novel | c.1207N>G | p.Lys403Glu | p.K403E | Q9NYY3 | protein_coding | tolerated(1) | benign(0.001) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
10769 | PLK2 | CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | | US8598172, 1 | | |
10769 | PLK2 | CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | inhibitor | 178102294 | BI-2536 | |
10769 | PLK2 | CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | inhibitor | 249565601 | ONVANSERTIB | |
10769 | PLK2 | CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | | BI2536 | | |
10769 | PLK2 | CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE | | WORTMANNIN | WORTMANNIN | 17135248 |